US · Healthcare · Health Information Services
EPS came in at 0.31 against a street estimate of 0.14 — a beat of 121.4%.
Analysts rate National Research Corp a buy (1 buy, 0 hold, 0 sell out of 1) with an average price target of $26.00.
| Fund | Stake |
|---|---|
| Kayne Anderson Rudnick Investment Management LLC | 9.18% |
| BlackRock Inc | 4.80% |
| Morgan Stanley - Brokerage Accounts | 3.88% |
| Vanguard Capital Management, LLC | 3.01% |
| Dimensional Fund Advisors, Inc. | 2.22% |
| Willis Investment Counsel | 1.97% |
| Geode Capital Management, LLC | 1.90% |
| QV Investors Inc | 1.68% |
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for National Research Corp — free to start.
Open in the appGoogle PlayApp StoreData updated 2026-10-19.